Jin Medical International Ltd. (NASDAQ:ZJYL - Get Free Report) saw a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 349,600 shares, a drop of 52.8% from the February 13th total of 740,800 shares. Currently, 0.9% of the shares of the company are short sold. Based on an average trading volume of 345,800 shares, the short-interest ratio is currently 1.0 days.
Jin Medical International Stock Up 4.4 %
Shares of ZJYL stock traded up $0.04 on Monday, reaching $0.89. The stock had a trading volume of 171,748 shares, compared to its average volume of 312,953. Jin Medical International has a 12 month low of $0.59 and a 12 month high of $4.77. The firm's 50-day moving average is $0.84 and its two-hundred day moving average is $1.49.
About Jin Medical International
(
Get Free Report)
Jin Medical International Ltd. engages in the design, development, manufacturing, and sale of wheelchair and other living aids products for people with disabilities or impaired mobility in China and internationally. It also offers oxygen concentrators and bathing machines. The company was founded in 2006 and is based in Changzhou, China.
Recommended Stories
Before you consider Jin Medical International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jin Medical International wasn't on the list.
While Jin Medical International currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.